Terms ending in 2042
Every in-force patent on Pharma Cinq, LLC's record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,758,570 | Uridine Triacetate Amorphous Formulation In force · High confidence | Wellstat Therapeutics Corporation | In force | High confidence | |
| US 12,558,368 | Compositions and Devices for Systemic Delivery of Uridine In force · High confidence | Pharma Cinq, LLC | In force | High confidence | |
| US 12,630,580 | 5'-O-Phenylacetyluridine and therapeutic use In force · High confidence | Pharma Cinq, LLC | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
2 of these are in force and held by Pharma Cinq, LLC.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.